Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization

ACS Chemical Neuroscience

Volumn 2, Issue 9, 2011, Pages 544-552

  Nolan, Tammy L ^a   Lapinsky, David J ^a   Talbot, Jeffery N ^b   Indarte, Martín ^c   Liu, Yi ^a   Manepalli, Sankar ^a   Geffert, Laura M ^a   Amos, Mary Ellen ^b   Taylor, Phillip N ^b   Madura, Jeffry D ^a   Surratt, Christopher K ^a  

^a DUQUESNE UNIVERSITY   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Depression; Molecular docking; Molecular hybridization; Monoamine; Neurotransmitter transporter; Virtual screening

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; DJLDU 3 79; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MALE; MOLECULAR HYBRIDIZATION; MOUSE; NONHUMAN; TAIL SUSPENSION TEST; VIRTUAL REALITY; VIRTUAL SCREENING;

EID: 84857861948     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn200044x     Document Type: Article

References (63)

1. Amara, S., and Sonders, M. S. (1998) Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 51, 87-96.
2. Hahn, M. K., Robertson, D., and Blakely, R. D. (2003) A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J. Neurosci. 23, 4470-4478.
3. Bowton, E., Saunders, C., Erreger, K., Sakrikar, D., Matthies, H. J., Sen, N., Jessen, T., Colbran, R. J., Caron, M. G., Javitch, J. A., Blakely, R. D., and Galli, A. (2010) Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J. Neurosci. 30, 6048-6057.
4. Wong, D. F., Harris, J. C., Naidu, S., Yokoi, F., Marenco, S., Dannals, R. F., Ravert, H. T., Yaster, M., Evans, A., Rousset, O., Bryan, R. N., Gjedde, A., Kuhar, M. J., and Breese, G. R. (1996) Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc. Natl. Acad. Sci. U.S.A. 93, 5539-5543.
5. Prasad, H. C., Steiner, J. A., Sutcliffe, J. S., and Blakely, R. D. (2009) Enhanced activity of human serotonin transporter variants associated with autism. Philos. Trans. R. Soc. London Biol. Sci. 364, 163-173.
6. Hahn, M. K., and Blakely, R. D. (2002) Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics J. 2, 217-235.
7. Ramamoorthy, S., Bauman, A. L., Moore, K. R., Han, H., Yang- Feng, T., Chang, A. S., Ganapathy, V., and Blakely, R. D. (1993) Antidepressant- and cocaine-sensitive human serotonin transporter" Molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U.S.A. 90, 2542-2546.
8. Ozaki, N., Goldman, D., Kaye, W. H., Greenberg, B. D., Lappalainen, J., Rudnick, G., and Murphy, D. L. (2003) Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol. Psychiatry 8, 933-936.
9. Ferguson, J. M. (2001) SSRI antidepressant medications: Adverse effects and tolerability. Prim. Care Compan. J. Clin. Psychiatry 3, 22-27.
10. Kennedy, S. H., Andersen, H. F., and Lam, R. W. (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci. 31, 122-131.
11. Preskorn, S. H. (1995) Comparison of the tolerability of buproprion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry 56 (Suppl 6), 12-21.
12. Schellander, R., and Donnerer, J. (2010) Antidepressants: Clinically relevant drug interactions to be considered. Pharmacology 86, 203-215.
13. Gu, H., Wall, S. C., and Rudnick, G. (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269, 7124-7130.
14. McElvain, J. S., and Schenk, J. O. (1992) A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem. Pharmacol. 43, 2189-2199.
15. Rudnick, G. (2002) In Neurotransmitter Transporters, Structure, Function, and Regulation (Reith, M. E. A., Ed.), 2nd ed., pp 25-52, Humana Press, Totowa, NJ.
16. Beuming, T., Shi, L., Javitch, J. A., and Weinstein, H. (2006) A comprehensive structure-based alignment of prokaryotic and eukaryotic neurostransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol. Pharmacol. 70, 1630-1642.
17. Yamashita, A., Singh, S. K., Kawate, T., Jin, Y., and Gouaux, E. (2005) Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature 437, 215-223.
18. Andersen, J., Olsen, L., Hansen, K. B., Taboureau, O., Jorgensen, F. S., Jorgensen, A.M., Bang-Andersen, B., Egebjerg, J., Stromgaard, K., and Kristensen, A. S. (2009) Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter. J. Biol. Chem. 285, 2051-2063.
19. Forrest, L. R., Zhang, Y. W., Jacobs, M. T., Gesmonde, J., Xie, L., Honig, B. H., and Rudnick, G. (2008) Mechanism for alternating access in neurotransmitter transporters. Proc. Natl. Acad. Sci. U.S.A. 105, 10338-10343.
20. Indarte, M., Madura, J. D., and Surratt, C. K. (2008) Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAa leucine transporter as a template. Proteins 70, 1033-1046.
21. Sarker, S., Weissensteiner, R., Steiner, I., Sitte, H. H., Ecker, G. F., Freissmuth, M., and Sucic, S. (2010) The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol. Pharmacol. 78, 1026-1035.
22. Beuming, T., Kniazeff, J., Bergmann, M. L., Shi, L., Gracia, L., Raniszewska, K., Newman, A. H., Javitch, J. A., Weinstein, H., Gether, U., and Loland, C. J. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat. Neurosci. 11, 780-789.
23. Boudker, O., and Verdon, G. (2010) Structural perspectives on secondary active transporters. Trends Pharmacol. Sci. 31, 418-426.
24. Shi, L., Quick, M., Zhao, Y., Weinstein, H., and Javitch, J. A. (2008) The mechanism of a neurotransmitter:sodium symporter-inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol. Cell 30, 667-677.
25. Zhao, Y., Terry, D. S., Shi, L., Quick, M., Weinstein, H., Blanchard, S. C., and Javitch, J. A. (2011) Substrate-modulated gating dynamics in a Na(+)-coupled neurotransmitter transporter homologue. Nature 474, 109-113.
26. Sinning, S., Musgaard, M., Jensen, M., Severinsen, K., Celik, L., Koldso, H., Meyer, T., Bols, M., Jensen, H. H., Schiott, B., and Wiborg, O. (2010) Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter. J. Biol. Chem. 285, 8363-8374.
27. Thompson, B. J., Jessen, T., Henry, L. K., Field, J. R., Gamble, K. L., Gresch, P. J., Carneiro, A. M., Horton, R. E., Chisnell, P. J., Belova, Y., McMahon, D. G., Daws, L. C., and Blakely, R. D. (2011) Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter. Proc. Natl. Acad. Sci. U.S.A. 108, 3785-3790.
28. Singh, S. K., Yamashita, A., and Gouaux, E. (2007) Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448, 952-956.
29. Zhou, Z., Zhen, J., Karpowich, N. K., Goetz, R. M., Law, C. J., Reith, M. E. A., and Wang, D. N. (2007) LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317, 1390-1393.
30. Zhou, Z., Zhen, J., Karpowich, N. K., Law, C. J., Reith, M. E. A., and Wang, D.-N. (2009) Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol. 16, 652-657.
31. Andersen, J., Taboureau, O., Hansen, K. B., Olsen, L., Egebjerg, J., Stromgaard, K., and Kristensen, A. S. (2009) Location of the antidepressant binding site in the serotonin transporter: Importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. J. Biol. Chem. 284, 10276-10284.
32. Bailey, D., and Brown, D. (2001) High-throughput chemistry and structure-based design: survival of the smartest. Drug Discovery Today 6, 57-59.
33. Schneider, G., and Bohm, H. J. (2002) Virtual screening and fast automated docking methods. Drug Discovery Today 7, 64-70.
34. Indarte, M., Liu, Y., Madura, J. D., and Surratt, C. K. (2010) Receptor-based discovery of a plasmalemmal monoamine transporter inhibitor via high-throughput docking and pharmacophore modeling. ACS Chem. Neurosci. 1, 223-233.
35. (2010) Molecular Operating Environment (MOE), In 2010.10, Chemical Computing Group Inc., Montreal, QC, Canada.
36. Butler, S. G., and Meegan, M. J. (2008) Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter. Curr. Med. Chem. 15, 1737-1761.
37. Zhou, D., Stack, G. P., Lo, J., Failli, A. A., Evrard, D. A., Harrison, B. L., Hatzenbuhler, N. T., Tran, M., Croce, S., Yi, S., Golembieski, J., Hornby, G. A., Lai, M., Lin, Q., Schecter, L. E., Smith, D. L., Shilling, A. D., Huselton, C., Mitchell, P., Beyer, C., and Andree, T. H. (2009) Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists. J. Med. Chem. 52, 4955-4959.
38. Herold, F., Chodkowski, A., Izbicki, L., Turlo, J., Dawidowski, M., Kleps, J., Nowak, G., Stachowicz, K., Dybala, M., Siwek, A., Mazurek, A. P., Mazurek, A., and Plucinski, F. (2011) Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3. Eur. J. Med. Chem. 46, 142-149.
39. Herold, F., Izbicki, Ł., Chodkowski, A., Dawidowski, M., Król, M., Kleps, J., Turzo, J., Wolska, I., Nowak, G., and Stachowicz, K. (2009) Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity: Part 2. Eur. J. Med. Chem. 44, 4702-4715.
40. Tomlinson, I. D., Iwamoto, H., Blakely, R. D., and Rosenthal, S. J. (2011) Biotin tethered homotryptamine derivatives: high affinity probes of the human serotonin transporter (hSERT). Bioorg. Med. Chem. Lett. 21, 1678-1682.
41. Viegas-Junior, C., Danuello, A., da Silva Bolzani, V., Barreiro, E. J., and Fraga, C. A. M. (2007) Molecular hybridization: A useful tool in the design of new drug prototypes. Curr. Med. Chem. 14, 1829-1852.
42. Sun, F., Xu, G., Wu, J., and Yang, L. (2006) Efficient lipasecatalyzed kinetic resolution of 4-arylmethoxy-3-hydroxybutanenitriles: Application to an expedient synthesis of a statin intermediate. Tetrahedron: Asymmetry 17, 2907-2913.
43. Foquerna, S., Miralpeix, M., Pages, L., Puig, C., Cardus, A., Anton, F., Cardenas, A., Vilella, D., Aparici, M., Calaf, E., Prieto, J., Gras, J., Huerta, J. M., Warrellow, G., Beleta, J., and Ryder, H. (2004) Synthesis and structure-activity relationships of novel histamine H1 antagonists: Indolylpiperidinyl benzoic acid derivatives. J. Med. Chem. 47, 6326-6337.
44. Chan, A. W., Curran, T. T., Iera, S., Sellstedt, J. H., Vid, G., Feigelson, G., Ding, Z. (2002) Processes for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino-[2,3-f] quinoline, U.S. Patent WO/2002/092602.
45. Cryan, J. F., and Holmes, A. (2005) The ascent of mouse: advances in modeling human depression and anxiety. Nat. Rev. Drug Discovery 4, 775-790.
46. Steru, L., Chermat, R., Thierry, B., and Simon, P. (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Heidelberg, Ger.) 85, 367-370.
47. Kim, C. Y., Mahaney, P. E., McConnell, O., Zhang, Y., Manas, E., Ho, D. M., Deecher, D. C., and Trybulski, E. J. (2009) Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol- 1-yl)-3-phenylpropan-2-ols. Bioorg. Med. Chem. Lett. 19, 5029-5032.
48. O'Neill, D. J., Adedoyin, A., Alfinito, P. D., Bray, J. A., Cosmi, S., Deecher, D. C., Fensome, A., Harrison, J., Leventhal, L., Mann, C., McComas, C. C., Sullivan, N. R., Spangler, T. B., Uveges, A. J., Trybulski E. J., Whiteside, G. T., and Zhang, P. (2010) Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). J. Med. Chem. 53, 4511-4521.
49. Tebben, A. J., and Schnur, D. M. (2011) Beyond rhodopsin: G protein-coupled receptor structure and modeling incorporating the beta2-adrenergic and adenosine alpha2A crystal structures. Methods Mol. Biol. 672, 359-386.
50. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K., and Stevens, R. C. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318, 1258-1265.
51. Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Edwards, P. C., Henderson, R., Leslie, A. G., Tate, C. G., and Schertler, G. F. (2008) Structure of a beta1-adrenergic G-proteincoupled receptor. Nature 454, 486-491.
52. Chien, E. Y., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., Shi, L., Newman, A. H., Javitch, J. A., Cherezov, V., and Stevens, R. C. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095.
53. Ahmed, A., Choo, H., Cho, Y. S., Park, W. K., and Pae, A. N. (2009) Identification of novel serotonin 2C receptor ligands by sequential virtual screening. Bioorg. Med. Chem. 17, 4559-4568.
54. Isberg, V., Balle, T., Sander, T., Jorgensen, F. S., and Gloriam, D. E. (2011) G protein- and agonist-bound serotonin 5-HT(2A) receptor model activated by steered molecular dynamics simulations. J. Chem. Inf. Model. 51, 315-325.
55. Renault, N., Gohier, A., Chavatte, P., and Farce, A. (2010) Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model. Eur. J. Med. Chem. 45, 5086-5099.
56. Simpson, L. M., Wall, I. D., Blaney, F. E., and Reynolds, C. A. (2011) Modeling GPCR active state conformations: The beta(2) -adrenergic receptor. Proteins 79, 1441-1457.
57. Ivetac, A., and McCammon, J. A. (2010) Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. Chem. Biol. Drug Des. 76, 201-217.
58. Kazius, J., McGuire, R., and Bursi, R. (2005) Derivation and validation of toxicophores for mutagenicity prediction. J. Med. Chem. 48, 312-320.
59. (2010) Discovery Studio Modeling Environment, 2.5.1 ed., Accelrys Software Inc., San Diego.
60. Celik, L., Sinning, S., Severinsen, K., Hansen, C. G., Moller, M. S., Bols, M., Wiborg, O., and Schiott, B. (2008) Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. J. Am. Chem. Soc. 130, 3853-3865.
61. Still, W. C., Kahn, M., and Mitra, A. (1978) Rapid chromatographic technique for preparative separations with moderate resolution. J. Org. Chem. 43, 2923-2925.
62. Talbot, J. N., Jutkiewicz, E. M., Graves, S. M., Clemans, C. F., Nicol, M. R., Huang, X., Mortensen, R. M., Neubig, R. R., and Traynor, J. R. (2010) RGS inhibition selectively potentiates serotonin-mediated antidepressant effects. Proc. Natl. Acad. Sci. U.S.A. 107, 11086-11091.
63. (2008) PyMOL Molecular Graphics System, Mac OS X ed., Schrodinger, LLC, New York.